Dimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Dimensional Fund Advisors LP lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 15.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 341,305 shares of the company's stock after selling 62,658 shares during the quarter. Dimensional Fund Advisors LP owned 0.89% of Tarsus Pharmaceuticals worth $18,897,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Summit Investment Advisors Inc. boosted its stake in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $25,000. Bank of New York Mellon Corp boosted its position in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock valued at $5,644,000 after purchasing an additional 498 shares during the last quarter. Swiss National Bank boosted its holdings in Tarsus Pharmaceuticals by 1.2% in the fourth quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after purchasing an additional 600 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after buying an additional 789 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Price Performance

Shares of TARS traded down $2.27 during mid-day trading on Friday, reaching $44.87. The company had a trading volume of 529,648 shares, compared to its average volume of 689,361. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market capitalization of $1.89 billion, a P/E ratio of -11.78 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The company's 50-day moving average is $48.26 and its 200-day moving average is $49.14.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Guggenheim boosted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $66.33.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares in the company, valued at approximately $3,273,628.80. This trade represents a 9.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares of the company's stock, valued at approximately $2,322,849.05. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.